A Phase 1, Open-Label, Dose-Finding Study of INCB050465 in Combination With Investigator Choice of Rituximab, Bendamustine and Rituximab, or Ibrutinib in Participants With Previously Treated B-Cell Lymphoma (CITADEL-112)
Phase of Trial: Phase I
Latest Information Update: 25 Aug 2018
At a glance
- Drugs Parsaclisib (Primary) ; Bendamustine; Ibrutinib; Rituximab
- Indications B cell lymphoma; Diffuse large B cell lymphoma; Follicular lymphoma; Mantle-cell lymphoma; Marginal-zone-B-cell-lymphoma
- Focus Adverse reactions
- Acronyms CITADEL-112
- Sponsors Incyte Corporation
- 26 Jun 2018 Status changed from not yet recruiting to recruiting.
- 15 May 2018 Planned End Date changed from 15 Nov 2020 to 13 Dec 2019.
- 15 May 2018 Planned primary completion date changed from 15 Nov 2019 to 13 Dec 2019.